Yun Zhong Takes on New Role at Wedbush Securities
Wedbush Securities, a highly regarded independent financial services firm, has recently appointed Yun Zhong, PhD, as Senior Vice President within their Equity Research team, focusing on biotechnology. This strategic move aims to bolster their research capabilities and deepen their engagement within the ever-evolving biotech sector.
Expanding Biotech Research Coverage
Dr. Zhong is set to lead the coverage of eight dynamic stocks that span various key areas of biotechnology, such as Ascendis Pharma, BioMarin Pharmaceuticals, Keros Therapeutics, MoonLake Immunotherapeutics, Passage Bio, Protagonist Therapeutics, Rezolute, and Voyager Therapeutics. This effort not only demonstrates Wedbush's commitment to enhancing its Healthcare Equity Research but also reflects a dedication to providing clients with valuable insights into a robust selection of biotech investments.
A Wealth of Experience
Having previously worked with Jefferies, Dr. Zhong brings a wealth of knowledge regarding therapeutic mechanisms and current trends in biotechnology. His impressive career path includes tenure at Cowen and Company and senior roles at recognized firms like SunTrust Robinson Humphrey and BTIG. His comprehensive expertise covers critical areas including orphan diseases, genetic medicine, hematology, and more, equipping him with unique insights that will significantly benefit his new team.
Welcoming Comments from Leadership
Upon joining Wedbush Securities, Dr. Zhong expressed excitement about the opportunity, stating, "Joining Wedbush is a remarkable chance to become part of a respected firm with a strong presence in biotechnology. The collaborative spirit here is truly exceptional, and I look forward to contributing to our research initiatives alongside such a talented team."
According to Kevin Merritt, Director of Research, "Yun's in-depth expertise and extensive knowledge of the field will markedly enhance our Healthcare Research team’s capabilities. His insights are expected to be invaluable as we work diligently to deliver top-tier analysis for our clients in this dynamic sector."
Educational Background
Dr. Zhong boasts an impressive academic background, having earned his PhD in neuroscience and molecular biology from Rockefeller University. Additionally, he holds both a Master of Science and a Bachelor of Science in biophysical engineering from Osaka University in Japan, preparing him well for the high-stakes world of biotechnology research.
About Wedbush Securities
Founded in 1955, Wedbush Securities is the largest subsidiary of Wedbush Financial Services and has established itself as a prominent figure in the financial industry. The firm is well-known for its extensive offerings, which include securities brokerage, wealth management, and investment banking solutions tailored to both private and institutional clients. Based in Los Angeles, Wedbush operates 100 registered offices and employs nearly 900 professionals who uphold a dedication to exceptional client service, financial security, and innovation.
Frequently Asked Questions
What is the role of Yun Zhong at Wedbush Securities?
Yun Zhong serves as the Senior Vice President of Equity Research, specializing in biotechnology.
Which biotech stocks will Dr. Zhong cover?
Dr. Zhong will cover stocks including Ascendis Pharma, BioMarin Pharmaceuticals, and others in the biotech field.
What prior experience does Dr. Zhong bring?
Dr. Zhong has a background with Jefferies and has held senior positions at notable firms, bringing extensive knowledge of biotechnology.
What is Wedbush Securities known for?
Wedbush Securities is recognized for its comprehensive financial services, including brokerage and investment banking.
Where is Wedbush Securities headquartered?
The firm is headquartered in Los Angeles, California, with numerous registered offices across the country.
